BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 24392981)

  • 1. A Bayesian approach to subgroup identification.
    Berger JO; Wang X; Shen L
    J Biopharm Stat; 2014; 24(1):110-29. PubMed ID: 24392981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian assessment of the influence and interaction conditions in multipopulation tailoring clinical trials.
    Millen BA; Dmitrienko A; Song G
    J Biopharm Stat; 2014; 24(1):94-109. PubMed ID: 24392980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian subgroup analysis with a zero-enriched Polya Urn scheme.
    Sivaganesan S; Laud PW; Müller P
    Stat Med; 2011 Feb; 30(4):312-23. PubMed ID: 21225894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian approach to noninferiority trials for proportions.
    Gamalo MA; Wu R; Tiwari RC
    J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semiparametric bayesian testing procedure for noninferiority trials with binary endpoints.
    Osman M; Ghosh SK
    J Biopharm Stat; 2011 Sep; 21(5):920-37. PubMed ID: 21830923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A flexible strategy for testing subgroups and overall population.
    Alosh M; Huque MF
    Stat Med; 2009 Jan; 28(1):3-23. PubMed ID: 18985704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of statistical and regulatory issues in the planning, analysis, and interpretation of subgroup analyses in confirmatory clinical trials.
    Hemmings R
    J Biopharm Stat; 2014; 24(1):4-18. PubMed ID: 24392975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-to-event analysis with treatment arm selection at interim.
    Di Scala L; Glimm E
    Stat Med; 2011 Nov; 30(26):3067-81. PubMed ID: 21898523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bayesian credible subgroups approach to identifying patient subgroups with positive treatment effects.
    Schnell PM; Tang Q; Offen WW; Carlin BP
    Biometrics; 2016 Dec; 72(4):1026-1036. PubMed ID: 27159131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subgroups: time to go back to basic statistical principles?
    Keene ON; Garrett AD
    J Biopharm Stat; 2014; 24(1):58-71. PubMed ID: 24392978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian statistics in medical devices: innovation sparked by the FDA.
    Campbell G
    J Biopharm Stat; 2011 Sep; 21(5):871-87. PubMed ID: 21830920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size estimation in single-arm clinical trials with multiple testing under frequentist and Bayesian approaches.
    Zaslavsky BG; Scott J
    J Biopharm Stat; 2012; 22(4):819-35. PubMed ID: 22651117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A hybrid Bayesian adaptive design for dose response trials.
    Chang M; Chow SC
    J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detecting qualitative interaction: a Bayesian approach.
    Bayman EO; Chaloner K; Cowles MK
    Stat Med; 2010 Feb; 29(4):455-63. PubMed ID: 19950107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bayesian subgroup analysis using collections of ANOVA models.
    Liu J; Sivaganesan S; Laud PW; Müller P
    Biom J; 2017 Jul; 59(4):746-766. PubMed ID: 28319254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian statistical methods in public health and medicine.
    Etzioni RD; Kadane JB
    Annu Rev Public Health; 1995; 16():23-41. PubMed ID: 7639872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian models for subgroup analysis in clinical trials.
    Jones HE; Ohlssen DI; Neuenschwander B; Racine A; Branson M
    Clin Trials; 2011 Apr; 8(2):129-43. PubMed ID: 21282293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of statistical planning to address subgroups in confirmatory clinical trials.
    Koch GG; Schwartz TA
    J Biopharm Stat; 2014; 24(1):72-93. PubMed ID: 24392979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
    Jiang Z; Song Y; Shou Q; Xia J; Wang W
    Trials; 2014 Dec; 15():500. PubMed ID: 25528466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing simultaneous hypotheses in pharmaceutical trials: a Bayesian approach.
    Dominici F
    J Biopharm Stat; 1998 May; 8(2):283-97. PubMed ID: 9598423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.